Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 AnalysisSteven L. Flamm,David L. Wyles,Stanley Wang,David J. Mutimer, Jrgen K. Rockstroh,Yves J. Horsmans,Paul Y. Kwo,Ola Weiland,Erica Villa,Jeong Heo,Edward J. Gane,Stephen D. Ryder,Tania M. Welzel,Teresa Ng,Sandra S. Lovell,Ran Liu,Preethi Krishnan,Sarah Kopecky-Bromberg,Armen Asatryan,Roger Trinh,Federico J. MensaHEPATOLOGY(2017)引用 0|浏览28暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要